CYTO T 101
Alternative Names: CYTO T-101Latest Information Update: 26 Mar 2021
At a glance
- Originator CytoImmune Therapeutics
- Developer CytoImmune Therapeutics; HRAIN Biotechnology
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Mar 2021 CytoImmune Therapeutics and Hrain Biotechnology plan to expand the development in Acute myeloid leukaemia (CytoImmune Therapeutics' pipeline, March 2021)
- 17 Mar 2021 CytoImmune Therapeutics and Hrain Biotechnology plan a phase I trial for Cancer in China (Parenteral) (CytoImmune Therapeutics' pipeline, March 2021)
- 17 Mar 2021 CytoImmune Therapeutics and Hrain Biotechnology plan a phase II trial for Cancer in China (Parenteral) (CytoImmune Therapeutics' pipeline, March 2021)